SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Oct 6, 2009
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: Oct. 6, 2009 · CIK: 0000818686 · Accession: 0000899140-09-001626
AI Filing Summary & Sentiment
File numbers found in text: 000-16174
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Form 20-F for the Fiscal Year Ended December 31, 2008 filed February 27, 2009 Form 6-K filed May 7, 2009 File No. 000-16174
Re:
Dear Mr. Rosenberg:
I refer to your letter to me dated July 29, 2009, containing comments of the Staff of the Securities and Exchange Commission relating to the above-referenced filings with the SEC, and our responses thereto, sent on our behalf on August 13, 2009. In connection with such responses to the Staff’s comments, on behalf of Teva, I acknowledge that:
•
Teva is responsible for the adequacy and accuracy of the disclosure in its filings with the SEC;
•
Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and
•
Teva may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Eyal Desheh
Show Raw Text
CORRESP
1
filename1.htm
VIA EDGAR
October 05, 2009
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporation Finance
Re:
Teva Pharmaceutical Industries Limited (“Teva”)
Form 20-F for the Fiscal Year Ended December 31, 2008
filed February 27, 2009
Form 6-K filed May 7, 2009
File No. 000-16174
Dear Mr. Rosenberg:
I refer to your letter to me dated July 29, 2009, containing comments of the Staff of the Securities and Exchange Commission relating to the above-referenced filings with the SEC, and our responses thereto, sent on our behalf on August 13, 2009. In connection with such responses to the Staff’s comments, on behalf of Teva, I acknowledge that:
•
Teva is responsible for the adequacy and accuracy of the disclosure in its filings with the SEC;
•
Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and
•
Teva may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Eyal Desheh
Eyal Desheh
Chief Financial Officer
cc:
Mark Brunhofer (SEC)
Ibolya Ignat (SEC)
Shimrit Shem-Tov (Teva)
Uzi Karniel (Teva)
Richard S. Egosi (Teva)
Peter H. Jakes (Willkie Farr)
Jeffrey S. Hochman (Willkie Farr)